C4 Therapeutics (CCCC) Q1 2024 Earnings
CCCC·Reported May 8, 2024·Before market open
C4 Therapeutics reported Q1 2024 revenue of $3.0M, missed analyst consensus of $8.1M by $5.1M. Diluted EPS came in at $-0.41.
Revenue
$3.0Mmissed by $5.1M
Consensus: $8.1MDiluted EPS
$-0.41met estimate
Consensus: $-0.41
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about C4 Therapeutics's Q1 2024 earnings report.
C4 Therapeutics (CCCC) reported Q1 2024 earnings on May 8, 2024 before market open.
C4 Therapeutics reported revenue of $3.0M and diluted EPS of $-0.41 for Q1 2024.
Revenue missed the consensus estimate of $8.1M by $5.1M. EPS beat the consensus estimate of $-0.41 by $0.00.
You can read the 10-Q periodic report (0001628280-24-021368) directly on SEC EDGAR. The filing index links above go to sec.gov.